Malte Peters is the President and Chief Executive Officer of Tango Therapeutics since January 2026 and has served on the Tango board of directors since 2018. Most recently, he served as Chief Research and Development Officer of MorphoSys AG, a biopharmaceutical company, and prior to that served as its Chief Development Officer and member of its management board since March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in Oncology Translational Medicine at Novartis. Malte held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Malte received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. He received his habilitation in Internal Medicine from the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.